Skip to main content

Clinical Trials Using Isatuximab

Review the clinical trials studying isatuximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
Using Isatuximab to Treat Low Blood Cell Counts Following Allogeneic Hematopoietic Cell Transplantation in People With Blood Cancer
Status: Active
Location: 7 locations
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 4 locations
Isatuximab, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: 4 locations
Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: 3 locations
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: 3 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Status: Active
Location: 4 locations
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Isatuximab plus Lenalidomide After Autologous Hematopoietic Stem Cell Transplantation for Treatment of High-Risk Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Elranatamab and Isatuximab for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for the Treatment of Multiple Myeloma in Ultra-Frail Patients
Status: Approved
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Isatuximab with or without Lenalidomide in Treating Patients with High Risk Smoldering Plasma Cell Myeloma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas